Literature DB >> 8570826

Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries?

R Snow1, J D Babish, A M McBean.   

Abstract

To learn whether the risk of revaccination in adults should limit its use, the authors investigated whether adverse events requiring hospitalization occurred in a group of Medicare enrollees revaccinated with pneumococcal polysaccharide vaccine. A prospective cohort analysis and case study of revaccinated people involved five percent of all elderly Medicare enrollees from 1985 through 1988, consisting of 66,256 people receiving one dose of vaccine and 1,099 receiving two doses. Comparison was made of the hospitalization rate within 30 days after revaccination and rates of singly vaccinated persons using discharge diagnosis for all those hospitalized during the 30 days after revaccination. No significant difference was found between the hospitalization rate of the revaccinated cohort and comparison group. No adverse reactions attributable to pneumococcal polysaccharide vaccine causing hospitalization were identified among 39 revaccinated persons who were hospitalized within 30 days of revaccination. Revaccination of elderly Medicare beneficiaries does not cause events serious enough to require hospitalization. Vaccination of persons according to the Public Health Service Immunization Practice Advisory Committee guidelines is recommended when the prior immunization status is unknown.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8570826      PMCID: PMC1381815     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  8 in total

1.  Pneumococcal vaccine efficacy in selected populations in the United States.

Authors:  G Bolan; C V Broome; R R Facklam; B D Plikaytis; D W Fraser; W F Schlech
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

Review 2.  Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

Authors:  M R Hilleman; A J Carlson; A A McLean; P P Vella; R E Weibel; A F Woodhour
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

3.  The clinical effectiveness of pneumococcal vaccine in the elderly.

Authors:  R V Sims; W C Steinmann; J H McConville; L R King; W C Zwick; J S Schwartz
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

4.  Immunization of elderly people with polyvalent pneumococcal vaccine.

Authors:  D Fedson; J Henrichsen; P H Mäkelä; R Austrian
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

5.  A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

Authors:  E D Shapiro; J D Clemens
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

6.  The utilization of pneumococcal polysaccharide vaccine among elderly Medicare beneficiaries, 1985 through 1988.

Authors:  A M McBean; J D Babish; R Prihoda
Journal:  Arch Intern Med       Date:  1991-10

7.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

8.  Severe local reactions to pneumococcal vaccine.

Authors:  K Nelson; J A Goldman; C A Perlino
Journal:  South Med J       Date:  1980-02       Impact factor: 0.954

  8 in total
  2 in total

1.  Validation of influenza and pneumococcal vaccine status in adults based on self-report.

Authors:  P Mangtani; A Shah; J A Roberts
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

2.  Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Authors:  Ken B Waites; Kay C Canupp; Yu-Ying Chen; Michael J DeVivo; Moon H Nahm
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.